Tags : Mvasi


Insights+ Key Biosimilars Events of August 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of biosimilar space […]Read More

Biosimilars Biotech Regulatory

Amgen and Allergan’s Mvasi (bevacizumab, biosimilar) + Combination Therapy Receives

Shots: The approval is based on P-III study results assessing Mvasi vs bevacizumab in patients with non-squamous NSCLC The study demonstrated in biosimilarity of Mvasi with bevacizumab in terms of efficacy, safety and immunogenicity Mvasi (bevacizumab, biosimilar) is a IgG1 mAb, binds to VEGF and inhibits the interaction of VEGF with its receptors, VEGF receptor-1 […]Read More